Department of Radiation Oncology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa 247-8533, Japan.
Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8573, Japan.
Br J Radiol. 2020 Jul;93(1111):20200311. doi: 10.1259/bjr.20200311. Epub 2020 May 14.
Boron neutron capture therapy (BNCT) has great potential to selectively destroy cancer cells while sparing surrounding normal cells. The basic concept of BNCT was developed in the 1930s, but it has not yet been commonly used in clinical practice, even though there is now a large number of experimental and translational studies demonstrating its marked therapeutic potential. With the development of neutron accelerators that can be installed in medical institutions, accelerator-based BNCT is expected to become available at several medical institutes around the world in the near future. In this commentary, from the point of view of radiation microdosimetry, we discuss the biological effects of BNCT, especially the underlying mechanisms of compound biological effectiveness. Radiobiological perspectives provide insight into the effectiveness of BNCT in creating a synergy effect in the field of clinical oncology.
硼中子俘获治疗（BNCT）具有选择性破坏癌细胞而不损伤周围正常细胞的巨大潜力。BNCT 的基本概念是在 20 世纪 30 年代发展起来的，但即使现在有大量的实验和转化研究表明其具有显著的治疗潜力，它仍未在临床实践中得到广泛应用。随着可安装在医疗机构中的中子加速器的发展，基于加速器的 BNCT有望在不久的将来在世界各地的几个医学研究所中使用。在这篇评论中，我们从辐射微剂量学的角度讨论了 BNCT 的生物学效应，特别是复合生物效应的潜在机制。放射生物学观点深入了解了 BNCT 在临床肿瘤学领域产生协同效应的有效性。
